COMP <GO>
PRGO vs HRMY // PIOTROSKI F-SCORE QUALITY
Perrigo Company plc (NYSE) VS. Harmony Biosciences Holdings Inc. (NASDAQ) • 15-METRIC TALLY: PRGO 2
— HRMY 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: HRMY
LAST: $15.90 (-0.13%) • MKT CAP: $2.21B
piotroski-score
5/9
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRGO VS. HRMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRGO | HRMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.10% | 77.20% | -42.10 | HRMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.60% | 63.00% | -76.60 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.58% | 15.48% | -8.90 | HRMY | /fcf-yield <GO> |
| Operating Margin | -26.40% | 24.00% | -50.40 | HRMY | /operating-margins <GO> |
| Net Profit Margin | -33.50% | 18.30% | -51.80 | HRMY | /net-margins <GO> |
| Revenue Growth (YoY) | -2.80% | 21.50% | -24.30 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 7.22% | 0.00% | +7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.38 | -5.18 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 9/9 | -4.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.7 | 50.0 | +6.70 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 11.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.21B | $2.25B | -$40.9M | HRMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRGO REV | HRMY REV | PRGO GROSS % | HRMY GROSS % | PRGO FCF | HRMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.25B | $868.5M | 35.1% | 77.2% | $145.1M | $347.9M |
| FY 2024 | $4.37B | $714.7M | 35.3% | 78.1% | $244.6M | $218.7M |
| FY 2023 | $4.66B | $582.0M | — | — | $405.5M | $219.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRGO // BETA —
HRMY // BETA —